Picture1.png
Sacks Parente Golf Appoints Doug Samuelson as Chief Financial Officer
September 09, 2024 08:15 ET | Sacks Parente Golf, Inc.
CAMARILLO, CA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- NEWTON GOLF: A Sacks Parente Company (Nasdaq: SPGC) (“NEWTON GOLF” or the “Company”), a technology-forward golf company with a growing portfolio of...
22157.jpg
Global Oncolytic Virus Immunotherapy Market 2024-2030: IMLYGIC, Oncorine, Delytact Availability, Dosage, Price Analysis,Opportunity & Clinical Trials Insights
September 05, 2024 04:33 ET | Research and Markets
Dublin, Sept. 05, 2024 (GLOBE NEWSWIRE) -- The "Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
September 03, 2024 16:01 ET | Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
August 14, 2024 16:05 ET | Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
July 30, 2024 07:00 ET | Genelux Corporation
WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
22157.jpg
Global Oncolytic Virus Therapy Industry Research 2024-2032: Strategic Collaborations to Increase Market Share, Oncolytic Wild-type Viruses Driving Therapeutic Innovation, North America Leads
June 27, 2024 06:03 ET | Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Global Oncolytic Virus Therapy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies...
22157.jpg
Oncolytic Virus Cancer Therapy Pipeline Analysis, 2024 - Showing Promise with Over 120 Companies and 125 Drugs in Development
June 14, 2024 06:51 ET | Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.The field of oncolytic virus...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
May 24, 2024 08:00 ET | Genelux Corporation
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
May 23, 2024 16:01 ET | Genelux Corporation
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
22157.jpg
Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight - A USD 1.50 Billion+ Market Opportunity by 2030
May 14, 2024 08:50 ET | Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering....